10余年前在一项侵袭性曲霉病的随机临床试验中,已证实伏立康唑疗效优于两性霉素B,因此前者被公认为治疗曲霉病的首选抗真菌药。此后相继研发了对曲霉及毛霉有效的新的三唑类药物如泊沙康唑、艾沙康唑。Maertens和他的研究小组进行了一项随机对照、双盲非劣性试验,在527例侵袭性曲霉病(占75%)和其他丝状真菌感 More than 10 years ago in a randomized clinical trial of invasive aspergillosis, voriconazole has been shown to be superior to amphotericin B and is therefore recognized as the preferred antifungal agent for the treatment of aspergillosis. Since then, new triazole drugs such as posaconazole and isaconazole, which are effective against Aspergillus and Mucor, have been developed. Maertens and his team conducted a randomized, double-blind non-inferiority trial of 527 invasive aspergillosis (75%) and other filamentous fungal infections